CRISPR THERAPEUTICS AG (CRSP) Stock Fundamental Analysis
NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to CRSP. CRSP was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRSP as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRSP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CRSP had negative earnings in the past year.
CRSP had a negative operating cash flow in the past year.
CRSP had negative earnings in 4 of the past 5 years.
In the past 5 years CRSP reported 4 times negative operating cash flow.
1.2 Ratios
CRSP's Return On Assets of -17.80% is fine compared to the rest of the industry. CRSP outperforms 79.21% of its industry peers.
CRSP's Return On Equity of -21.08% is amongst the best of the industry. CRSP outperforms 84.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.8% | ||
| ROE | -21.08% | ||
| ROIC | N/A |
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CRSP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRSP has more shares outstanding
Compared to 5 years ago, CRSP has more shares outstanding
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.76 indicates that CRSP is not in any danger for bankruptcy at the moment.
CRSP's Altman-Z score of 7.76 is amongst the best of the industry. CRSP outperforms 83.33% of its industry peers.
CRSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.76 |
ROIC/WACCN/A
WACC4.9%
2.3 Liquidity
A Current Ratio of 15.64 indicates that CRSP has no problem at all paying its short term obligations.
CRSP has a Current ratio of 15.64. This is amongst the best in the industry. CRSP outperforms 88.89% of its industry peers.
CRSP has a Quick Ratio of 15.64. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
CRSP has a better Quick ratio (15.64) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.64 | ||
| Quick Ratio | 15.64 |
3. Growth
3.1 Past
The earnings per share for CRSP have decreased strongly by -66.18% in the last year.
The Revenue for CRSP has decreased by -86.13% in the past year. This is quite bad
CRSP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.62% yearly.
EPS 1Y (TTM)-66.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.49%
Revenue 1Y (TTM)-86.13%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%71.63%
3.2 Future
Based on estimates for the next years, CRSP will show a very strong growth in Earnings Per Share. The EPS will grow by 28.44% on average per year.
Based on estimates for the next years, CRSP will show a very strong growth in Revenue. The Revenue will grow by 172.22% on average per year.
EPS Next Y-26.45%
EPS Next 2Y-2.14%
EPS Next 3Y5.89%
EPS Next 5Y28.44%
Revenue Next Year213.35%
Revenue Next 2Y239.6%
Revenue Next 3Y199.57%
Revenue Next 5Y172.22%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CRSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.14%
EPS Next 3Y5.89%
5. Dividend
5.1 Amount
CRSP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.13
+10.04 (+18.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners76.63%
Inst Owner Change0%
Ins Owners1.69%
Ins Owner Change0.26%
Market Cap5.62B
Analysts77.14
Price Target81.69 (25.43%)
Short Float %30.08%
Short Ratio8.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.61%
Min EPS beat(2)-23.86%
Max EPS beat(2)63.08%
EPS beat(4)3
Avg EPS beat(4)18.42%
Min EPS beat(4)-23.86%
Max EPS beat(4)63.08%
EPS beat(8)6
Avg EPS beat(8)218.16%
EPS beat(12)9
Avg EPS beat(12)153.76%
EPS beat(16)11
Avg EPS beat(16)124.7%
Revenue beat(2)1
Avg Revenue beat(2)128.37%
Min Revenue beat(2)-86.95%
Max Revenue beat(2)343.7%
Revenue beat(4)1
Avg Revenue beat(4)19.94%
Min Revenue beat(4)-91.33%
Max Revenue beat(4)343.7%
Revenue beat(8)3
Avg Revenue beat(8)481.23%
Revenue beat(12)4
Avg Revenue beat(12)324.33%
Revenue beat(16)6
Avg Revenue beat(16)272.51%
PT rev (1m)0%
PT rev (3m)-0.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.2%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-10.17%
Revenue NQ rev (1m)-4.33%
Revenue NQ rev (3m)-30.35%
Revenue NY rev (1m)-1.17%
Revenue NY rev (3m)-15.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 149.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.07 | ||
| P/tB | 3.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.52
EYN/A
EPS(NY)-4.56
Fwd EYN/A
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-3.55
OCFYN/A
SpS0.44
BVpS21.18
TBVpS21.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.8% | ||
| ROE | -21.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.23% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.64 | ||
| Quick Ratio | 15.64 | ||
| Altman-Z | 7.76 |
F-Score2
WACC4.9%
ROIC/WACCN/A
Cap/Depr(3y)74.64%
Cap/Depr(5y)175.56%
Cap/Sales(3y)1036.11%
Cap/Sales(5y)1149.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.49%
EPS Next Y-26.45%
EPS Next 2Y-2.14%
EPS Next 3Y5.89%
EPS Next 5Y28.44%
Revenue 1Y (TTM)-86.13%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%71.63%
Revenue Next Year213.35%
Revenue Next 2Y239.6%
Revenue Next 3Y199.57%
Revenue Next 5Y172.22%
EBIT growth 1Y-58.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.16%
EBIT Next 3Y0.42%
EBIT Next 5Y20.04%
FCF growth 1Y18.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.86%
OCF growth 3YN/A
OCF growth 5YN/A